BioMérieux

The deal comes one week after the Netherlands said it was buying 9.2 million of the tests. The Canadian government is also purchasing 2,172 BD Veritor Plus Systems.

The firm saw 120 percent growth in the BioFire FilmArray product line driven by strong demand for a respiratory panel which can detect SARS-CoV-2.

Fujirebio Diagnostics got the nod for a chemiluminescent enzyme immunoassay to measure levels of CA 15-3 and manage patients diagnosed with breast cancer.

Baxter will distribute BioMérieux's Nephroclear CCL14 diagnostic in Europe and the US following regulatory approval and launch in those markets.

For the second quarter, sales for its clinical applications jumped nearly 14 percent, while industrial applications fell 7 percent year over year.

According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.

The panel tests for 23 pathogens covering 19 viruses, including SARS-CoV-2, and four bacteria that are responsible for the most frequent respiratory infections.

The firm expects organic revenue growth of approximately 11 percent at constant exchange rates compared to the second quarter last year.